Replicor in the News
Presentation of Replicor’s clinical data at major Liver Disease conferences continues to generate interest in the press on the effects of NAPs in patients infected with HBV and HDV. Links to these articles are found below.
| ARTICLE TITLE | ARTICLE LINK | ||
|---|---|---|---|
| 18.06.2018 | Combination HBV therapy shows functional control 24 weeks after cessation | Healio | link |
| 29.11.2017 | REP 2139 combination therapy leads to functional control of hepatitis B virus | InfoHep | link |
| 28.11.2017 | Treating viral hepatitis | Pan European Networks | link |
| 24.10.2017 | Tiny hep B drug combo study touts potential of a ‘functional cure’ at little-known Replicor | Endpoints News | link |
| 24.10.2017 | Most patients achieve control of HBV with combined interferon therapy | Healio | link |
| 23.10.2017 | Replicor HBV Combo Leads to Functional Control | BioCentury | link |
| 09.10.2017 | Combined interferon therapy safe, tolerable in HBV/HDV coinfection | Healio | link |
| 01.2017 | Highlights in Hepatitis B Virus Treatment From the 2016 Annual Meeting of the American Association for the Study of Liver Diseases | Gastroenterology & Hepatology (Vol 13, Issue 1) | link |
| 27.11.2016 | Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus | InfoHep | link |
| World Hepatitis Alliance | link | ||
| HIV and Hepatitis | link | ||
| 17.11.2016 | Novel Treatment Could Lead to Functional Control of Hep B | Medscape | link |
| 16.11.2016 | Infusion-Based Therapies Show Promise in HBV – early results with REP 2139 and REP 2165 suggest clearance of surface antigen | MedPage Today | link |
| 15.11.2016 | REP-2165, REP-2139 show efficacy for HBV when combined with TDF, PEG-IFN | Healio | link |
| 15.11.2015 | AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection | HIV and Hepatitis | link |
| 15.5.2015 | Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta | InfoHep | link |